Focusing on current urgent and unmet medical needs, the Innovative Small Molecules Research Institute are committed to developing new small molecule therapeutics. We aim for comprehensive understandings of the disease biology and establishment of innovative, high-value portfolio.
Pipeline | S/N | Product number | Product introduction |
---|---|---|---|
Kidney Diseases |
1 | JMKX000189 | Multiple organ autoimmune diseases have significant advantages in efficacy and safety |
2 | JMKX003142 | Significant advantages in efficacy and safety for hereditary chronic kidney disease | |
3 | JMKX003002 | Chronic kidney disease complicated with metabolic diseases, with significant advantages in preclinical data | |
4 | JMKX004649 | Common immune nephropathy with significant unmet needs | |
Oncology | 5 | JMKX001899 | Non small cell lung cancer, good brain penetration, high safety, and potential for breakthrough therapy |
6 | JMKX000197 | Targeting FIC and First Indication, local manifestations have therapeutic advantages | |
7 | JMKX003948 | Simultaneously inhibiting multiple tumor specific growth factors, effective against multiple tumor species | |
8 | JMKX003561 | Innovative targets, preclinical data shows significant inhibition of specific cancer species growth | |
Cardiovascular Diseases | 9 | JMKX001149 | Treat and prevent thrombotic diseases while reducing potential bleeding risks |
10 | JMKX003142 | Through intravenous administration, suitable for the treatment scenario of cardiovascular and cerebrovascular diseases | |
Respiratory Diseases | 11 | JMKX003801 | Targeting drug-resistant bacterial infections, a novel broad-spectrum approach β- lactamase inhibitor |
12 | JMKX003676 | The target is fungal infection, with low liver toxicity and better safety than existing drugs | |
Pain | 13 | JMKX000623 | It has a significant inhibitory effect on various pain models and has entered the clinical stage |
Malignant tumor has been a major threat. Currently around 4 million new cases are reported every year in China.
ღ
The small molecule anti-tumor drugs are developed against oncogenes. Once absorbed, these drugs specifically bind to their targets, leading to the apoptosis induction and proliferation inhibition of tumor cells. Targeted drugs show much higher specificity, better efficacy, and less toxicity, as compared to conventional chemotherapeutic agents.